| J Gavin Gonzalez, MD | |
|
4140 E Baseline Rd, Ste 211, Mesa, AZ 85206 | |
| (480) 273-8680 | |
| (480) 306-7683 |
| Full Name | J Gavin Gonzalez |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 31 Years |
| Location | 4140 E Baseline Rd, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427027408 | NPI | - | NPPES |
| 26245 | Other | AZ | AZ MEDICAL BOARD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 26245 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Ent Pc | 8729149711 | 65 |
News Archive
Two drugs tested in a larger trial did not improve kidney function in acute heart failure patients, contrary to results of smaller studies. The results were presented today at the American Heart Association's Scientific Sessions 2013 in Dallas and simultaneously published in the Journal of the American Medical Association. Previous smaller studies showed that low-dose dopamine or low-dose nesiritide could improve kidney function and reduce fluid overload that is often present in hospitalized acute heart failure patients by increasing urine production.
EMC Corporation (NYSE: EMC), the world leader in information infrastructure solutions, today announced that eClinicalWorks, a market leader in ambulatory clinical systems with more than 25,000 healthcare provider customers, has consolidated and enhanced security of its IT infrastructure using EMC, RSA and VMware solutions.
For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology, suggest the need for persistent cancer screening and prevention in these patients.
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19 months would earn 43 percent patient share, according to surveyed U.S. neurologists. In comparison, in Europe, such an agent would earn a slightly lower patient share of 30 percent, according to surveyed European neurologists. This lower share estimate is possibly a result of higher price sensitivity of European markets.
› Verified 6 days ago
| Entity Name | Valley Ent Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508990185 PECOS PAC ID: 8729149711 Enrollment ID: O20120202000209 |
News Archive
Two drugs tested in a larger trial did not improve kidney function in acute heart failure patients, contrary to results of smaller studies. The results were presented today at the American Heart Association's Scientific Sessions 2013 in Dallas and simultaneously published in the Journal of the American Medical Association. Previous smaller studies showed that low-dose dopamine or low-dose nesiritide could improve kidney function and reduce fluid overload that is often present in hospitalized acute heart failure patients by increasing urine production.
EMC Corporation (NYSE: EMC), the world leader in information infrastructure solutions, today announced that eClinicalWorks, a market leader in ambulatory clinical systems with more than 25,000 healthcare provider customers, has consolidated and enhanced security of its IT infrastructure using EMC, RSA and VMware solutions.
For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology, suggest the need for persistent cancer screening and prevention in these patients.
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19 months would earn 43 percent patient share, according to surveyed U.S. neurologists. In comparison, in Europe, such an agent would earn a slightly lower patient share of 30 percent, according to surveyed European neurologists. This lower share estimate is possibly a result of higher price sensitivity of European markets.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| J Gavin Gonzalez, MD 4140 E Baseline Rd, Ste 211, Mesa, AZ 85206 Ph: (480) 273-8680 | J Gavin Gonzalez, MD 4140 E Baseline Rd, Ste 211, Mesa, AZ 85206 Ph: (480) 273-8680 |
News Archive
Two drugs tested in a larger trial did not improve kidney function in acute heart failure patients, contrary to results of smaller studies. The results were presented today at the American Heart Association's Scientific Sessions 2013 in Dallas and simultaneously published in the Journal of the American Medical Association. Previous smaller studies showed that low-dose dopamine or low-dose nesiritide could improve kidney function and reduce fluid overload that is often present in hospitalized acute heart failure patients by increasing urine production.
EMC Corporation (NYSE: EMC), the world leader in information infrastructure solutions, today announced that eClinicalWorks, a market leader in ambulatory clinical systems with more than 25,000 healthcare provider customers, has consolidated and enhanced security of its IT infrastructure using EMC, RSA and VMware solutions.
For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology, suggest the need for persistent cancer screening and prevention in these patients.
Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19 months would earn 43 percent patient share, according to surveyed U.S. neurologists. In comparison, in Europe, such an agent would earn a slightly lower patient share of 30 percent, according to surveyed European neurologists. This lower share estimate is possibly a result of higher price sensitivity of European markets.
› Verified 6 days ago
Raquel A Redtfeldt, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 4140 E Baseline Rd, Suite 211, Mesa, AZ 85206 Phone: 480-273-8680 Fax: 480-306-7683 | |
Thomas J Ketterer, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 560 W Brown Rd, #1008, Mesa, AZ 85201 Phone: 480-833-8620 | |
Glenn B. Rothman, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1520 S. Dobson Road, Suite 305, Mesa, AZ 85202 Phone: 602-539-4000 Fax: 602-833-3040 | |
Robert Henry Thompson Iii, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2058 S Dobson Rd, #10, Mesa, AZ 85202 Phone: 480-730-0707 Fax: 480-730-6893 | |
Leopold K Yin, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 4140 E Baseline Rd, Suite 211, Mesa, AZ 85206 Phone: 480-273-8680 Fax: 480-306-7683 | |
Dr. Janelle A. Y. Engel, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1520 S. Dobson Road, Suite 305, Mesa, AZ 85202 Phone: 480-539-4000 Fax: 480-833-3040 |